1.00
-0.0242(-2.37%)
Currency In USD
| Previous Close | 1.02 |
| Open | 1.03 |
| Day High | 1.04 |
| Day Low | 0.94 |
| 52-Week High | 2.18 |
| 52-Week Low | 0.65 |
| Volume | 303,905 |
| Average Volume | 219,798 |
| Market Cap | 46.99M |
| PE | -0.46 |
| EPS | -2.15 |
| Moving Average 50 Days | 0.93 |
| Moving Average 200 Days | 1.18 |
| Change | -0.02 |
If you invested $1000 in Opus Genetics, Inc. (IRD) since IPO date, it would be worth $12,447.5 as of May 09, 2025 at a share price of $0.996. Whereas If you bought $1000 worth of Opus Genetics, Inc. (IRD) shares 0 years ago, it would be worth $771.94 as of May 09, 2025 at a share price of $0.996.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate
GlobeNewswire Inc.
May 06, 2025 12:00 PM GMT
- FDA RMAT designation recognizes encouraging early data from Opus’ Phase 1/2 trial in patients with LCA5, an ultra-rare inherited retinal diseaseRESEARCH TRIANGLE PARK, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a cl
Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision
GlobeNewswire Inc.
May 05, 2025 12:00 PM GMT
Improvements in subjective and objective measures of efficacy observed at six months persisted for one year in patients with severe vision impairment from inherited retinal degeneration due to mutations in the LCA5 gene Administration of OPGx-LCA5 by
Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases
GlobeNewswire Inc.
Apr 08, 2025 12:00 PM GMT
First pediatric patient shows encouraging early safety profile and meaningful improvement in visual function at one month A second pediatric patient was recently dosed, and the pediatric cohort is expected to complete enrollment in Q2 2025; initial d